Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $21.8 million.

  • Contineum Therapeutics' Net Cash Flow rose 16012.55% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 9254.6%. This contributed to the annual value of $6.4 million for FY2024, which is 3555.29% down from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Net Cash Flow is $21.8 million, which was up 16012.55% from -$1.7 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Net Cash Flow high stood at $61.0 million for Q2 2024, and its period low was -$36.3 million during Q3 2024.
  • For the 3-year period, Contineum Therapeutics' Net Cash Flow averaged around $3.4 million, with its median value being $527000.0 (2025).
  • In the last 5 years, Contineum Therapeutics' Net Cash Flow crashed by 84977.44% in 2024 and then soared by 16012.55% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Net Cash Flow (Quarter) stood at -$2.0 million in 2023, then crashed by 849.77% to -$18.9 million in 2024, then skyrocketed by 215.31% to $21.8 million in 2025.
  • Its last three reported values are $21.8 million in Q3 2025, -$1.7 million for Q2 2025, and $527000.0 during Q1 2025.